ライフサイエンスコーパス: angina

1 elevation myocardial infarction; 6% unstable angina).

2 0.8% patients with ACS and 39.2% with stable angina).

3 itated cardiac arrest, revascularization, or angina).

4 oke, transient ischemic attack, and unstable angina.

5 smokers, and to have more comorbidities and angina.

6 otentially, improve appropriate treatment of angina.

7 ans independently quantified their patients' angina.

8 ents, given their high prevalence of post-MI angina.

9 o not include subgroup analysis for unstable angina.

10 ffect of stem/progenitor cells in refractory angina.

11 ients with a new diagnosis of chronic stable angina.

12 in 1 man was downgraded from AMI to unstable angina.

13 oke, as well as hospitalization for unstable angina.

14 m 4% to 80% for mortality and 12% to 59% for angina.

15 spasm, which led to the diagnosis of variant angina.

16 27% for 5-year mortality and 27% for 1-year angina.

17 sociated with under-recognition of patients' angina.

18 ardial perfusion in patients with refractory angina.

19 inical domains beyond the confines of stable angina.

20 s importance in patients with chronic stable angina.

21 l stroke) or hospital admission for unstable angina.

22 senting a risk factor for the development of angina.

23 pass graft (CABG) surgery than those without angina.

24 atal stroke, or hospitalization for unstable angina.

25 At baseline, 770 patients (64%) reported angina.

26 a limit their use mostly to the treatment of angina.

27 ncluding 141 MIs and 84 episodes of unstable angina.

28 regarding the use of angiography in unstable angina.

29 w CD133(+) cells in patients with refractory angina.

30 ial infarction (0.88 [0.72-1.07]; p=0.18) or angina (0.95 [0.73-1.23]; p=0.70), but we noted an adver

31 ischaemic stroke (1.72 [1.52-1.95]), stable angina (1.62 [1.49-1.77]), heart failure (1.56 [1.45-1.6

32 rval, 1.17-1.98), angiographically confirmed angina (1.91; 1.59-2.29), coronary artery bypass graft s

33 .53 to 2.10; p = 0.88) and those with stable angina (11.6% vs. 15.8%; HR: 0.82; 95% CI: 0.50 to 1.343

34 e MI group (7.5%) compared with the unstable angina (2.7%) and non-ACS (2.6%) groups (P < .001).

35 readmission included nonspecific chest pain/angina (24%) and heart failure (11%).

36 ectively randomized 350 patients with stable angina (55% women; aged 55+/-10 years), mostly with an i

37 was similar in patients with ACS and stable angina (6.61 [4.91-7.72] versus 6.62 [5.27-8.73], P=0.63

38 ercutaneous coronary intervention for stable angina (77.9% versus 46.2%).

39 , 3.8% versus 5.9%; P=0.24; and freedom from angina, 93.6% versus 90.2%; P=0.35).

40 cardiac ischemia (myocardial infarction and angina) (adjusted, 0.97 [0.78-1.22]) and stroke (adjuste

41 heart failure, cerebrovascular accident, or angina after the index angiography.

42 rediction models for long-term mortality and angina among 1613 patients with diabetes mellitus discha

43 ion, nonfatal stroke, or hospitalization for angina among individuals with no history of cardiovascul

44 on acute coronary syndromes (MI and unstable angina) among IRIS participants.

45 (mean age, 65.2+/-7.6 years) with exertional angina and coronary artery disease underwent cardiac cat

46 The association of smoking with angina and health-related quality of life (HRQOL) after

47 Ranolazine both treats chronic angina and improves glucose control.

48 at ranolazine would be effective in reducing angina and improving quality of life (QOL) in incomplete

49 l trial in which 2,604 patients with chronic angina and incomplete revascularization following percut

50 Likewise, clinical scenarios with unstable angina and intermediate- or high-risk features were deem

51 on is common in patients with chronic stable angina and is associated with increased morbidity and mo

52 aneous coronary intervention (PCI) in stable angina and is commonly observed clinically.

53 d more chronic disease states such as stable angina and ischemic cardiomyopathy.

54 The mechanisms governing exercise-induced angina and its alleviation by the most commonly used ant

55 wn about race and sex differences in post-MI angina and long-term risk of unplanned rehospitalization

56 tients with diabetes mellitus (DM) have less angina and more silent ischemia when compared with those

57 disease compared with men, the prevalence of angina and mortality from ischemic heart disease is high

58 ther understanding of the clinical impact of angina and nitroglycerin.

59 on acute coronary syndromes include unstable angina and non-ST-segment elevation myocardial infarctio

60 Angina and QOL questionnaires were collected at baseline

61 Questionnaire domains indicated worse 1-year angina and quality of life outcomes among patients rehos

62 tion was observed with respect to changes in angina and quality of life, cumulative diagnostic costs,

63 RETATION: In patients with medically treated angina and severe coronary stenosis, PCI did not increas

64 Although patients with less-frequent angina and those with heart failure more often had their

65 lack and female patients more likely to have angina and to be rehospitalized.

66 elevation acute coronary syndromes or stable angina and to evaluate long-term outcomes of nonenrolled

67 tor dysfunction is frequent in patients with angina and unobstructed coronaries in a European populat

68 tested as a means to improve recognition of angina and, potentially, improve appropriate treatment o

69 atal stroke, hospital admission for unstable angina, and hospital admission for heart failure, analys

70 ave a future role in treating heart failure, angina, and myocardial ischemia.

71 ry arteriosclerosis, essential hypertension, angina, and pre-infarction syndrome passed phenome-wide

72 ry of diabetes, hypertension, heart disease, angina, and stroke-all known to be associated with stati

73 ions for percutaneous coronary intervention, angina, and stroke.

74 w tract obstruction and symptoms of dyspnea, angina, and syncope.

75 (1) myocardial infarction (MI); (2) unstable angina; and (3) revascularization not associated with ac

76 The outcomes pooled were indices of angina (anginal episodes, Canadian Cardiovascular Societ

77 New therapies for refractory angina are needed.

78 RATIONALE: New therapies for refractory angina are needed.

79 function, coronary artery disease (CAD), and angina are often thought to have a worse prognosis and a

80 sease (CVD) (myocardial infarction, unstable angina, arterial revascularization, stroke, or cardiovas

81 , 29.7% had angina at 6 weeks, and 20.6% had angina at 1 year postdischarge.

82 , ranolazine's effect on glucose control and angina at 6 months was proportionate to baseline HbA1c,

83 nts, black patients were more likely to have angina at 6 weeks (female: 44.2% versus 31.8%; male: 33.

84 Overall, 29.7% had angina at 6 weeks, and 20.6% had angina at 1 year postdi

85 depression, female sex, and more symptomatic angina based on Canadian Cardiovascular Society class.

86 ded patients in Ontario, Canada, with stable angina based on obstructive coronary artery disease foun

87 95% CI 0.6, 6.1; P=0.02) and those with more angina (baseline SAQ angina frequency </=60; mean differ

88 chings that patients with DM experience less angina because of silent ischemia.

89 rgeted interventions to reduce the burden of angina because this presentation is clearly not benign.

90 ND In a 10-site US PCI registry, we assessed angina before and at 1, 6, and 12 months after elective

91 Patients with unstable angina benefit from an invasive management pathway initi

92 The strongest predictors for angina were angina burden in the 4 weeks before the AMI, younger age

93 Under-recognition of angina by physicians may result in undertreatment with r

94 especified subgroup of SIGNIFY patients with angina (Canadian Cardiovascular Society class score, >/=

95 ned as acute myocardial infarction, unstable angina, cardiogenic shock, ventricular arrhythmia, atrio

96 al episodes, Canadian Cardiovascular Society angina class, exercise tolerance, and antianginal medica

97 A multivariable model-including angina, congestive heart failure symptoms, shockable arr

98 ercutaneous coronary intervention for stable angina (CTO-PCI) is a rare but serious event.

99 nd nonfatal myocardial infarctions, unstable angina, deaths from coronary heart disease, fatal and no

100 Patients with typical angina decreased, whereas patients with dyspnea and atyp

101 Aortic valve stenosis (AS) can cause angina despite unobstructed coronary arteries, which may

102 urrent Canadian Cardiovascular Society II-IV angina, despite optimal medical therapy, >/=1 myocardial

103 urrent Canadian Cardiovascular Society II-IV angina, despite optimal medical therapy, >/=1 myocardial

104 eport of myocardial infarction and stroke or angina diagnosed by Rose Criteria.

105 tionate to baseline HbA1c, but the effect on angina dissipated by 12 months.

106 Angina does not predict all-cause mortality in medically

107 In patients with suspected angina due to coronary heart disease, CCTA leads to more

108 clinic visit, quantifying their frequency of angina during the previous month.

109 Dyspnea is a common angina equivalent that adversely affects quality of life

110 tic stenosis (AS) can manifest as exertional angina even in the presence of unobstructed coronary art

111 ing hip fractures, congestive heart failure, angina, falls, depression, cholecystitis, and total emer

112 ncident CVD (first definite angina, probable angina followed by revascularization, myocardial infarct

113 .6%; P=0.20) or symptoms (92.3% versus 94.8% angina free; P=0.25).

114 02) and those with more angina (baseline SAQ angina frequency </=60; mean difference 3.4; 95% CI 0.6,

115 r among ivabradine-treated patients, notably angina frequency (P<0.001) and disease perception (P=0.0

116 al limitation and a significant reduction in angina frequency (P=0.034).

117 yndrome) data, we examined 6-week and 1-year angina frequency and 1-year unplanned rehospitalization

118 examined race and sex differences in post-MI angina frequency and 1-year unplanned rehospitalization

119 ated to angina pectoris, notably in terms of angina frequency and disease perception.

120 to DES-PCI on several SAQ domains including angina frequency and physical function, as well as the r

121 ine's effect on Seattle Angina Questionnaire angina frequency at 6 and 12 months was tested.

122 icantly reduced Seattle Angina Questionnaire angina frequency at 6 months among DM patients but not a

123 and ivabradine patients had better scores on angina frequency at every visit to 36 months.

124 SAQ angina frequency repeated measures did not differ in adj

125 ve PCI with the Seattle Angina Questionnaire angina frequency score (range, 0-100, higher=better).

126 nd angina relief (mean difference in the SAQ angina frequency score for CABG vs. PCI of -0.9, 3.3, an

127 outcome (Seattle Angina Questionnaire [SAQ] angina frequency score) improved markedly, but similarly

128 , -1.53 (95% CI, -2.57 to -0.49) for the SAQ angina frequency score, 0.38 (95% CI, -0.51 to 1.27) for

129 e, -1.05 (95% CI, -2.12 to 0.02) for the SAQ angina frequency score, 0.38 (95% CI, -0.54 to 1.29) for

130 me physicians are more accurate in assessing angina frequency than others.

131 Angina frequency was categorized as none, monthly, and d

132 Improvement in SAQ angina frequency was observed with ranolazine at month 6

133 The reductions in angina frequency were numerically greater among patients

134 talization and tested for interactions among angina frequency, race, and sex.

135 The adjusted odds of MACE for the unstable angina group were similar to those for the non-ACS group

136 01) as well as a stricter definition without angina (HARD; ncases = 6,482) and selected cases with th

137 l stroke, admission to hospital for unstable angina, heart failure, and all-cause mortality.

138 condary outcomes were myocardial infarction, angina, heart failure, hypertension, arrhythmias, arteri

139 ction, arrhythmias, syncope, cardiomyopathy, angina, heart transplantation and coronary bypass grafts

140 atal stroke, hospital admission for unstable angina, hospital admission for heart failure, developmen

141 atal stroke, hospital admission for unstable angina, hospital admission for heart failure, or impaire

142 se death, myocardial infarction, or unstable angina hospitalization over a median follow-up of 26.1 m

143 nonfatal myocardial infarction, and unstable angina hospitalization was similar and fair for both CAC

144 of death, myocardial infarction, or unstable angina hospitalization.

145 as death, myocardial infarction, or unstable angina hospitalizations over a median follow-up of 26.1

146 ssociated with a worse prognosis; 2) whether angina identified patients who had a greater survival be

147 was MI in 32.8% of the procedures, unstable angina in 33.8%, and non-ACS in 33.4%.

148 However, the burden of angina in diabetic versus nondiabetic patients after ele

149 efit from CABG; and 3) whether CABG improved angina in patients with LV systolic dysfunction and CAD.

150 or dysfunction is an important mechanism for angina in patients with unobstructed coronary arteries.

151 ion is increasingly recognized as a cause of angina in pulmonary arterial hypertension (PAH).

152 Among 1257 patients, 411 reported angina in the previous month, of whom 173 (42%) were und

153 for acute coronary syndrome (ACS) or stable angina, in whom there is angiographic evidence for obstr

154 fect of angiography on mortality in unstable angina, incorporating the results of additional cardiac

155 , whereas patients with dyspnea and atypical angina increased.

156 In patients with suspected angina, investigation by CMR resulted in a lower probabi

157 Chronic angina is a common manifestation of ischaemic heart dise

158 Angina is common in hypertrophic cardiomyopathy (HCM) an

159 Under-recognition of angina is common in routine clinical practice.

160 of LMCA compression in patients with PAH and angina is high.

161 Chronic angina is more common in patients with diabetes mellitus

162 oke, coronary revascularisation, or unstable angina; key secondary endpoint was the composite of card

163 All patients with PAH and angina or angina-like symptoms attending the center between May 1,

164 tery (PA) in patients with PAH and angina or angina-like symptoms, determine the usefulness of screen

165 Of 765 patients with PAH, 121 had angina or angina-like symptoms.

166 indicated in patients with PAH and angina or angina-like symptoms.

167 nce of prior coronary artery bypass surgery, angina, low body mass index (<21 kg/m(2)), and falls wit

168 Better treatment of post-MI angina may improve patient quality of life and quality o

169 with myocardial infarction (n = 7) or stable angina (n = 10) underwent (18)F-NaF PET and prospective

170 Emergently admitted patients with unstable angina (n = 33 901) who did or did not receive angiograp

171 468), and patients with a history of CAD and angina (n=1003); patients with no known CAD or angina we

172 d angina: patients with no history of CAD or angina (n=2008), patients with no history of CAD but a h

173 =649), patients with a history of CAD but no angina (n=468), and patients with a history of CAD and a

174 ents with no history of CAD but a history of angina (n=649), patients with a history of CAD but no an

175 7], myocardial infarction [n = 5], unstable angina [n = 3], pericarditis [n = 2], arrhythmia [n = 12

176 ients were older than 18 years with unstable angina, non-ST segment elevation myocardial infarction (

177 re more likely than men to be readmitted for angina (odds ratio [95% confidence interval], 1.13 [1.04

178 dence interval, 1.89-4.95) and less-frequent angina (odds ratio for monthly angina [versus daily/week

179 Angina often persists or returns in populations followin

180 A total of 2037 participants with stable angina or an acute coronary syndrome who had an indicati

181 Among patients with stable angina or an acute coronary syndrome, an iFR-guided reva

182 All patients with PAH and angina or angina-like symptoms attending the center betw

183 lmonary artery (PA) in patients with PAH and angina or angina-like symptoms, determine the usefulness

184 Of 765 patients with PAH, 121 had angina or angina-like symptoms.

185 t CTCA is indicated in patients with PAH and angina or angina-like symptoms.

186 Eligible patients had stable or unstable angina or documented silent ischaemia, and a maximum of

187 .17 to 1.57), but no association with stable angina or intracerebral hemorrhage.

188 Unstable angina or non-ST-elevation myocardial infarction patient

189 ing PCI, there was no incremental benefit in angina or QOL measures by adding ranolazine in this angi

190 ion, stroke, hospital admission for unstable angina, or coronary revascularisation.

191 ion, stroke, hospital admission for unstable angina, or coronary revascularization.

192 rction, stroke, hospitalization for unstable angina, or coronary revascularization.

193 rction, stroke, hospitalization for unstable angina, or coronary revascularization.

194 atal stroke, hospital admission for unstable angina, or hospital admission for heart failure.

195 , congestive heart failure, stroke, incident angina, or intermittent claudication.

196 , but no differences in depressive symptoms, angina, or Type D personality when compared with men wit

197 amine the independent association of DM with angina over the year after treatment.

198 higher in ACS patients compared with stable angina patients (1.38 [1.16-1.52] versus 1.17 [1-1.31],

199 d cohort study on 49 556 adult ACS or stable angina patients with angiographic evidence of obstructiv

200 usive groups according to history of CAD and angina: patients with no history of CAD or angina (n=200

201 infarction (n=5371, 901 deaths), and stable angina pectoris (n=6536, 965 deaths) in 4 age categories

202 ve coronary angiography for suspected stable angina pectoris (SAP) (n = 4131) and an independent coho

203 75 in the best available therapy group) and angina pectoris (two [3%] of 74 in the ruxolitinib group

204 t-elevation myocardial infarction and stable angina pectoris , similar patterns were found albeit les

205 primarily for treatment of hypertension and angina pectoris and are thought to act as allosteric mod

206 Secondary endpoints were angina pectoris and hospitalization for heart failure.

207 The use of nitroglycerin in the treatment of angina pectoris began not long after its original synthe

208 Angina pectoris during RCA occlusion tended to occur in

209 intracoronary ECG ST-segment elevation, and angina pectoris during the same 1-minute coronary occlus

210 OR heart failure OR myocardial infarction OR angina pectoris OR acute coronary syndrome OR coronary a

211 re American region, older age, no history of angina pectoris or asthma, no use of hypoglycemic agent,

212 or revascularization, or with a diagnosis of angina pectoris or CHD defined by angiography.

213 ) undergoing coronary angiography for stable angina pectoris were studied.

214 s validated using CT images of patients with angina pectoris without known valvular disease (n = 95).

215 ovascular disorders, including hypertension, angina pectoris, and cardiac arrhythmia.

216 l infarction, CHD death, angiogram-confirmed angina pectoris, coronary artery bypass graft surgery, s

217 ar mortality, myocardial infarction, stroke, angina pectoris, hospitalization for heart failure, ESRD

218 ified in network meta-analyses of stroke and angina pectoris, limiting the conclusiveness of findings

219 ther self-reported QoL parameters related to angina pectoris, notably in terms of angina frequency an

220 atients had stable angina pectoris, unstable angina pectoris, or non-ST-elevation myocardial infarcti

221 t CVD, defined as new myocardial infarction, angina pectoris, or stroke, which developed between base

222 Eligible patients had stable angina pectoris, unstable angina pectoris, or non-ST-ele

223 each follow-up, patients with DM had similar angina prevalence and severity as those without DM.

224 rtery disease, history of stable or unstable angina, previous multi-vessel percutaneous coronary inte

225 zard ratios for incident CVD (first definite angina, probable angina followed by revascularization, m

226 alth status was quantified using the Seattle Angina Questionnaire (SAQ) and the 12-Item Short-Form He

227 , 12, 36, and 60 months by using the Seattle Angina Questionnaire (SAQ) and the 36-Item Short Form He

228 atients than in usual care patients: Seattle Angina Questionnaire 19.5 versus 11.4, p = 0.003; EuroQO

229 index PCI, the primary QOL outcome (Seattle Angina Questionnaire [SAQ] angina frequency score) impro

230 score, >/= 2 at baseline) using the Seattle Angina Questionnaire and a generic visual analogue scale

231 Health status was assessed using Seattle Angina Questionnaire and EuroQol-5D Visual Analog Scale.

232 s; and angina status assessed by the Seattle Angina Questionnaire and exercise testing at 6 and 12 mo

233 ine HbA1c and ranolazine's effect on Seattle Angina Questionnaire angina frequency at 6 and 12 months

234 bo, ranolazine significantly reduced Seattle Angina Questionnaire angina frequency at 6 months among

235 2 months after elective PCI with the Seattle Angina Questionnaire angina frequency score (range, 0-10

236 y outpatient practices completed the Seattle Angina Questionnaire before their clinic visit, quantify

237 visual analogue scale and the other Seattle Angina Questionnaire dimensions were higher among ivabra

238 Individual Seattle Angina Questionnaire domains indicated worse 1-year angi

239 e Duke Activity Status Index and the Seattle Angina Questionnaire frequency and QOL scales.

240 Similar results were seen for the Seattle Angina Questionnaire frequency scale (mean difference at

241 patient-oriented composite endpoint, Seattle Angina Questionnaire score, and exercise testing were no

242 One-year Seattle Angina Questionnaire summary scores were worse in patien

243 life as assessed with the use of the Seattle Angina Questionnaire was significantly improved in the t

244 validated clinical tool, such as the Seattle Angina Questionnaire, should be tested as a means to imp

245 e and 1, 12, and 36 months using the Seattle Angina Questionnaire, the 12-Item Short Form Health Surv

246 Cumulative angina rate based on adverse event reporting was analyse

247 Angina readmission accounted for 45% of the composite ou

248 dless of ethnicity, as well as high rates of angina readmission, highlight the need for more targeted

249 r myocardial infarction, unstable and stable angina, recent coronary artery bypass graft, and periphe

250 to diagnose ischemia in patients with stable angina referred for invasive coronary angiography.

251 To explore the effect of ivabradine on angina-related quality of life (QoL) in patients partici

252 ut also lead to an improvement in indices of angina, relevant clinical outcomes, and myocardial perfu

253 lexity (as assessed by the SYNTAX score) and angina relief (mean difference in the SAQ angina frequen

254 Angina relief at 5 years was enhanced with CABG among pa

255 trial of PCI versus a placebo procedure for angina relief that was done at five study sites in the U

256 In general, CABG resulted in greater angina relief, although the absolute treatment benefit w

257 In patients in whom unstable angina remains a concern or there is a desire to evaluat

258 reinfarction, rehospitalization for unstable angina, repeat coronary revascularization (target vessel

259 ial infarction, ischemic stroke, or unstable angina requiring hospitalization) in multivariable analy

260 tal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) was lower with alirocu

261 onally included hospitalisation for unstable angina requiring unplanned revascularisation) and in sen

262 onfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovasc

263 nd volumes by magnetic resonance imaging and angina severity.

264 or stroke) and any-CVD (MACE plus confirmed angina, silent MI, revascularization, or congestive hear

265 We tested a CAD phenotype inclusive of angina (SOFT; ncases = 10,801) as well as a stricter def

266 risation; device and procedural success; and angina status assessed by the Seattle Angina Questionnai

267 ng fatal and nonfatal myocardial infarction, angina, stroke, transient ischemic attack, and periphera

268 As they developed limiting angina, sublingual nitroglycerin was administered to hal

269 PCI with stenting, of whom 41 had sustained angina symptom relief.

270 D Patients referred for evaluation of stable angina symptoms underwent adenosine-stress dynamic compu

271 Angina symptoms were also better controlled in the exper

272 cian reporting a lower frequency category of angina than the patient.

273 ry artery disease and DM exhibit a burden of angina that is at least as high as those without DM desp

274 re seen to be effective for treating variant angina that manifested as a non-respiratory tract sympto

275 gnosis in 2 women was upgraded from unstable angina to AMI, and the diagnosis in 1 man was downgraded

276 nned coronary revascularization and unstable angina (UA) are common.

277 tion myocardial infarction (NSTEMI)/unstable angina (UA) who were managed medically without planned r

278 myocardial infarction [MI], stroke, unstable angina [UA] leading to hospitalization, coronary revascu

279 hose with heart failure more often had their angina under-recognized, most variation was unrelated to

280 luded 1,379 consecutive patients with stable angina, unobstructed coronaries and ACH test performed f

281 aphy within 2 months of their index unstable angina versus 0.097 (CI, 0.090 to 0.105) for those not r

282 ificant reduction of myocardial ischemia and angina versus placebo.

283 less-frequent angina (odds ratio for monthly angina [versus daily/weekly], 1.69; 95% confidence inter

284 depression after diagnosis of stable chronic angina was 18.8% over a mean follow-up of 1084 days.

285 This study investigated: 1) whether angina was associated with a worse prognosis; 2) whether

286 In the multivariable model, 6-week angina was most strongly associated with unplanned rehos

287 Angina was reported in 77.0% of these subjects, stroke i

288 Angina was significantly less severe in the PCI group at

289 riable, repeated-measures model, the risk of angina was similar over the year after PCI in patients w

290 glycosylated hemoglobin >7%, and persistent angina were all associated with increased risk, and prio

291 The strongest predictors for angina were angina burden in the 4 weeks before the AMI,

292 l infarction, and were not being treated for angina were randomly assigned to atorvastatin 10 mg dail

293 gina (n=1003); patients with no known CAD or angina were the reference group.

294 PCI, 2604 patients with a history of chronic angina who had ICR post-PCI were randomized 1:1 to oral

295 sation in patients with a history of chronic angina who had incomplete revascularisation after percut

296 ll-based therapy in patients with refractory angina who were ineligible for coronary revascularizatio

297 (aged >/=18 years) with a history of chronic angina with incomplete revascularisation after percutane

298 In patients with DM and chronic angina with incomplete revascularization after percutane

299 ary intervention report 1-year postdischarge angina, with black and female patients more likely to ha

300 th systolic heart failure and chronic stable angina without clinically significant adverse effects.